ROCKVILLE, Md., Oct. 31,
2023 /PRNewswire/ -- Shuttle Pharmaceuticals
Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes
of cancer patients treated with radiation therapy (RT), today
announced it has entered into an exclusive agreement to license
certain intellectual property (IP) from Georgetown University to advance Shuttle Pharma's
predictive biomarker program for prostate cancer.
The intellectual property was originally developed through a
collaboration of Shuttle Pharma scientists with investigators from
Georgetown University. The intellectual
property consists of patent applications prepared and filed by
Georgetown University titled:
"Predictive Biomarkers for Adverse Effects of Radiation
Therapy."
Shuttle Pharma's predictive marker strategy is to develop a
predictive diagnostic test for prostate cancer patients who are
considering elective radiation therapy which will allow them to
assess their risk for treatment success or failure, while informing
therapeutic decision making and follow-up management. Shuttle
Pharma believes a predictive diagnostic test for the effects of
radiation therapy would be a cost-effective approach to inform
clinicians in their treatment choices and provide patients with a
better understanding of the benefits and risks of radiation
therapy.
Anatoly Dritschilo, M.D., CEO of
Shuttle Pharma, commented, "Prostate cancers vary in their
aggressiveness and in their responses to treatment. Some prostate
cancers spread quickly to other parts of the body, while others
grow slowly and can be effectively managed by radiation therapy or
other conservative medical measures. While diagnostic tests are
available, presently there are no predictive diagnostics tests to
identify potential outcomes of available therapies. The key unmet
need of the diagnostic market is having a predictive, minimally
invasive blood test that provides the clinician and patient with a
measurement of the potential success of radiation therapy for their
cancer treatment. This unmet need in the market is what Shuttle's
predictive biomarker program looks to address."
The American Cancer Society estimates that 1 in 8 men will be
diagnosed with prostate cancer during his lifetime. The National
Cancer Institute of the National Institutes of Health (NIH)
Surveillance, Epidemiology, and End Results (SEER) database
estimated that approximately 268,000 men were diagnosed with
prostate cancer in the U.S. in 2022 and approximately 30% of
prostate cancer patients (~66,000) with localized disease received
radiation therapy for cancer treatment.
Dr. Dritschilo expanded, "Our mission is to accelerate
investigation of the prostate cancer metabolite-based predictive
assay to improve outcomes of radiation therapy. Shuttle Pharma aims
to change the way that clinicians select patients for radiation
therapy and provide informed consent. The potential market for
these predictive assays includes clinicians offering radiation
therapy for prostate cancer treatment in the initial selection
process and in personalizing follow up management of patients by
considering anticipated late effects."
Shuttle Pharma scientists have collaborated with investigators
from Georgetown University to complete Phase I and Phase II
NIH SBIR contracts to develop predictive biomarkers of radiation
therapy outcomes and late effects. Shuttle Pharma will also seek to
leverage eligibility to apply for project bridge funding via an NIH
Phase IIb SBIR mechanism.
About Shuttle Pharmaceuticals
Founded in 2012 by
faculty members of Georgetown
University, Shuttle Pharma is a discovery and development
stage specialty pharmaceutical company focused on improving the
outcomes for cancer patients treated with radiation therapy (RT).
Our mission is to improve the lives of cancer patients by
developing therapies that are designed to maximize the
effectiveness of RT while limiting the side effects of radiation in
cancer treatment. Although RT is a proven modality for treating
cancers, by developing radiation sensitizers, we aim to increase
cancer cure rates, prolong patient survival and improve quality of
life when used as a primary treatment or in combination with
surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release
about future expectations, plans and prospects, as well as any
other statements regarding matters that are not historical facts,
may constitute "forward-looking statements." These statements
include, but are not limited to, statements concerning the
development of our company. The words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including
factors discussed in the "Risk Factors" section of Shuttle Pharma's
Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on
March 15, 2023, and its Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2023 and June
30, 2023, filed with the SEC on May
25, 2023 and August 14, 2023,
respectively, as well other SEC filings. Any forward-looking
statements contained in this press release speak only as of the
date hereof and, except as required by federal securities laws,
Shuttle Pharmaceuticals specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharma-advances-prostate-cancer-predictive-biomarker-program-through-exclusive-license-agreement-301972185.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.